Gantenerumab

Drug Profile

Gantenerumab

Alternative Names: R-1450; RG-1450; RO-4909832

Latest Information Update: 01 Jul 2017

Price : $50

At a glance

  • Originator MorphoSys
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors; Amyloid beta-protein precursor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 22 Mar 2017 Roche completes a phase I trial in Healthy volunteers in USA (SC) (NCT02882009)
  • 01 Aug 2016 Roche initiates a phase I trial in Healthy volunteers in USA (SC) (NCT02882009)
  • 26 May 2016 Roche initiates a PET imaging substudy associated with the phase III Marguerite RoAD trial for Alzheimer's disease (early-stage disease) in the United Kingdom (UKCRN ID 16041)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top